ArticleAdvances in urology2012
Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now?
Article in Advances in urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma.Translational cancer research · 2020Review
- Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer.Cancer immunology, immunotherapy : CII · 2020Article
- Polymorphisms of genes encoding cytokines predict the risk of high-grade bladder cancer and outcomes of BCG immunotherapy.Central-European journal of immunology · 2020Article
- Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer.World journal of urology · 2018Article
- Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer.Bladder cancer (Amsterdam, Netherlands) · 2017Article
- Clinical Behavior of Bladder Urothelial Carcinoma in Young Patients: A Single Center Experience.Scientifica · 2016Article
- Pyuria predicts poor prognosis in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin.Molecular and clinical oncology · 2015Article
- Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer.PloS one · 2015Article
- Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.Urologic oncology · 2014Article
- Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy.British journal of cancer · 2013Article
- BCG immunotherapy for bladder cancer--the effects of substrain differences.Nature reviews. Urology · 2013Review
- Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy.Journal of immunotherapy (Hagerstown, Md. : 1997)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most effective therapeutic option for managing nonmuscle invasive bladder cancer (NMIBC), over the last 30 years, consists of intravesical instillations with the attenuated strain Bacillus Calmette-Guérin (the BCG vaccine). This has been performed as an adjuvant therapeutic to transurethral resection of bladder tumour (TURBT) and mostly directed towards patients with high-grade tumours, T1 tumours, and in situ carcinomas. However, from 20% to 40% of the patients do not respond and frequently present tumour progression. Since BCG effectiveness is unpredictable, it is important to find consistent biomarkers that can aid either in the prediction of the outcome and/or side effects development. Accordingly, we conducted a systematic critical review to identify the most preeminent predictive molecular markers associated with BCG response. To the best of our knowledge, this is the first review exclusively focusing on predictive biomarkers for BCG treatment outcome. Using a specific query, 1324 abstracts were gathered, then inclusion/exclusion criteria were applied, and finally 87 manuscripts were included. Several molecules, including CD68 and genetic polymorphisms, have been identified as promising surrogate biomarkers. Combinatory analysis of the candidate predictive markers is a crucial step to create a predictive profile of treatment response.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.